AIM ImmunoTech Secures Full Japanese Patent For Ampligen Use With Checkpoint Inhibitors In Cancer Treatment - AIM ImmunoTech (AMEX:AIM)
Published on March 18, 2026.
AIM ImmunoTech has secured a Japanese Patent for the use of Ampligen and Checkpoint Inhibitors in cancer treatment. The company is also known for its ability to use these substances in the treatment of cancer patients. The patent is also applied to the children of children who suffer from this disease.
Related Articles
Winner Of Massive $536M Mega Millions Jackpot Comes Forward
A woman in her 40s won the $536m Mega Millions jackpot, becoming the second largest online lottery prize in the United States.
Traders pour in billions ahead of Fed's 2PM decision
Large players are positioning aggressively for the Fed’s FOMC decision, amid rising inflation and market concerns, with Bitcoin hovering near $72,000 amid rising market volatility.
US wholesale prices spiked in February, reflecting pre-Iran war inflation pressures
US wholesale inflation surged to 0.7% in February due to higher food and service costs, despite a slight slowdown in consumer sentiment.